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The purpose of this study was to evaluate the hepatoprotective effect of an antioxidative nanoparticle (RNPN) recently developed
against APAP-induced hepatotoxicity in mice. The effects of oral administration of RNPN to APAP-treated mice were assessed for
various biochemical liver function parameters: alanine transaminase (ALT) activity, aspartate transaminase (AST) activity, alkaline
phosphatase (ALP) activity, prothrombin time, and serum albumin (ALB) level. The treatment effects were assessed in terms of
free radical parameters: malondialdehyde (MDA) accumulation, glutathione peroxidase (GPx) activity, % inhibition of superoxide
anion (O
2
−∙), and histopathological examination. The N-acetylcysteine (NAC)-treated group exhibited an enhanced prothrombin
time relative to the control group, while RNPN did not prolong prothrombin time. The RNPN-treated animals exhibited lower
levels of ALT, AST, and ALP, while increased ALB levels were measured in these animals compared to those in the other groups.
The RNPN-treated animals furthermore exhibited improved MDA levels, GPx activity, and % inhibition of O
2
−∙, which relate to
oxidative damage. Histological staining of liver tissues from RNPN-treated animals did not reveal any microscopic changes relative
to the other groups. The findings of this study suggest that RNPN possesses effective hepatoprotective properties and does not
exhibit the notable adverse effects associated with NAC treatment.
1. Introduction
Overdoses of acetaminophen (paracetamol, APAP, or N-
acetyl-p-aminophenol) represent one of the most common
pharmaceutical product poisonings in the world [1, 2].
Acetaminophen is widely used as an analgesic and antipyretic
drug; however, it is also the leading major cause of acute liver
failure (ALF) and acetaminophen overdose may lead to liver
transplantation being required or even to death, since the
early signs and symptoms of APAP-induced hepatotoxicity
are not clear [3–8]. The main mechanism of acetaminophen-
induced hepatotoxicity is an increase in oxidative stress and
subsequent saturation of the glucuronidation and sulfation
pathways of hepatic elimination, leading tomoreAPAP being
metabolized to N-acetyl-p-benzoquinone imine (NAPQI).
Finally, GSH depletion (∼70–80%) occurs and NAPQI binds
to liver cells, resulting in hepatotoxicity [9, 10].
N-Acetylcysteine (NAC), a precursor of glutathione
(GSH), is the standard antidote administered to patients
withAPAP-induced hepatotoxicity [11, 12]; however, NAChas
previously been shown to have adverse side effects including
bruising, bleeding, nausea, vomiting, and diarrhea or con-
stipation. Rarely, NAC also causes rashes, fever, headache,
drowsiness, low blood pressure, and liver problems, while
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NAC therapy was also shown to prolong prothrombin time
and should thus be avoided in patients with coagulation
disorders [13, 14]. Since NAC is a low molecular weight com-
pound, it furthermore displays a low stability and nonspecific
distribution in vivo physiological environments, resulting in
a low therapeutic efficacy.
Recently, the development of nanotherapeutic strategies
against APAP-induced liver injury has been the focus of
several research studies [15–18]. We have developed a novel
antioxidative nanoparticle, RNPN, prepared by self-assembly
of an amphiphilic block copolymer, methoxy-poly(ethylene
glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-1-oxyl) ami-
nomethylstyrene] (PEG-b-PMNT), which has nitroxide rad-
icals on the side chain of the hydrophobic segment. Due
to its amphiphilic nature, PEG-b-PMNT forms core-shell-
type polymeric micelles with tens of nanometers in size in
aqueous media [19]. We previously confirmed that the PEG-
b-PMNT polymer internalized and circulated in the blood
stream after oral administration of RNPN and is subsequently
disintegrated by the gastric acidity [20]. Since the nitroxide
radicals in the PMNT segment catalytically eliminate reactive
oxygen species (ROS), it functions as a strong antioxidant.
However, due to the high molecular weight of the PEG-b-
PMNT polymer, it is only minimally internalized in healthy
cells, thereby avoiding marked disturbances to normal redox
reactions such as those in the electron transport chain, which
is adversely affected by conventional low molecular weight
antioxidants [21]. On the basis of our previous investigations,
therefore, the effects of RNPN on APAP-induced liver injury
must be investigated. We report here on both the therapeutic
effect and the lack of adverse effects of orally administered
RNPN.
2. Materials and Methods
2.1. Materials. 1,1,3,3-Tetramethoxypropane (TMP), L-gluta-
thione reduced, glutathione peroxidase (GPx), glutathione
reductase (GR), xanthine, xanthine oxidase (XO), 𝛽-nico-
tinamide adenine dinucleotide 2󸀠-phosphate reduced tetra-
sodium (𝛽-NADPH) salt, APAP, and NAC were purchased
from the Sigma Chemical Company, St. Louis, MO, USA.
Other chemical reagents were analytical grade and milli-Q
water was used all through the experiments.
2.2. Preparation and Characterization of RNPN. PEG-b-
PMNT was synthesized as previously described [19]. The
molecular weight of the PEG segment and the degree of
polymerization of PMNT were determined as 5,000 and
13, respectively. The RNPN was prepared by self-assembly
of the PEG-b-PMNT using the dialysis method (Figure 1)
and the blank micelle (nRNP) was prepared in the same
way using PEG-b-poly(chloromethylstyrene), a precursor of
PEG-b-PMNT with the same molecular weight. The size and
distribution of the resulting RNPN and the nRNP in aqueous
solution were determined by dynamic light scattering (DLS)
measurements carried out in triplicate. Electron paramag-
netic resonance (EPR) was used to quantify the amount of
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Figure 1: Schematic illustration of antioxidative RNPN preparation.
2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) inside each
RNPN.
2.3. Animal Care Conditions. Animal experiments were
carried out using male CD-1® IGS mice nomenclature:
Crl:CD1(ICR) (10 weeks old, 40–50 g) purchased from
Charles River Japan, Inc. (Yokohama, Japan). The mice (𝑛 =
48) were maintained in the Laboratory Animal Resource
Center, University of Tsukuba (Japan), in six groups. The
animals were housed in stainless steel cages and seven days
prior to the experiment they were acclimated to the standard
laboratory conditions of 23 ± 1∘C, ventilation with relative
humidity of 50 ± 5%, and a 12 h light/12 h dark cycle. The
mice received food and filtered water ad libitum through-
out the study. All animal experiments were undertaken in
accordance with the criteria outlined in the license (numbers
15–434) approved by the Animal Ethics Committees of the
University of Tsukuba.
2.4. APAP-Induced Hepatotoxicity Model. Mice were ran-
domly divided into six groups of 8 animals each:
Group A: control, no treatment.
Group B: 0.9% normal saline (NSS) + APAP 2.5 g/kg
body weight (BW)
(the APAP concentration has been used accord-
ing to our pilot study).
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Figure 2: Experimental design of APAP-induced hepatotoxicity
model.
Group C: N-acetylcysteine (NAC) 600mg/kg BW +
APAP 2.5 g/kg BW.
Group D: low molecular weight (LMW) TEMPO
15.4mM + APAP 2.5 g/kg BW.
Group E: blank micelle (nRNP) 12.5mg/mL + APAP
2.5 g/kg BW.
Group F: RNPN 12.5mg/mL (containing 4-amino
TEMPO 15.4mM) + APAP 2.5 g/kg BW.
Prior to the APAP-induced hepatotoxicity experiments,
blood was collected from the tail veins of all mice to
analyze prothrombin time. All mice in the treatment groups
were orally administered their treatments once daily for 7
days after which hepatotoxicity was induced by oral gavage
of 2.5 g/kg BW of APAP (Figure 2). After 24 h, the mice
were rechecked of prothrombin time and anesthetized with
intraperitoneal (i.p.) injection of pentobarbital 50mg/kg BW.
The blood was drawn and treated with anticoagulant to
allow serum by centrifugation of the blood at 1600 g for
15min at 4∘C in order to determine the liver function.
Animals were then sacrificed and their livers were removed.
Half of each liver was fixed in 10% buffered formalin for
histopathology analysis and the other half was homogenized
(10% w/v) in ice cold phosphate buffer (50mM, pH 7.4).
The liver homogenates were centrifuged at 9,000 g for 15min
at 4∘C and the resulting supernatants were frozen at −80∘C
until being subjected to oxidative stress analysis and lipid
peroxidation assay.
2.5. Lipid Peroxidation (LPO) Assay. The levels of malon-
dialdehyde (MDA), the product of lipid peroxidation, were
assessed based on the method described by Ohkawa et al.
[22]. Briefly, the samples were treated with thiobarbituric
acid (TBA) to allow for thiobarbituric acid reactive substance
(TBARS), a pink complex and indicator of lipid peroxidation,
to be quantified. Absorbance levels at 532 nm were measured
by spectrophotometer and the arbitrary values obtained were
related to MDA concentration (nmol/g tissue) using a stan-
dard curve generated from the absorbance values obtained
for standard solutions of 1,1,3,3-tetramethoxypropane (TMP).
2.6. Glutathione Peroxidase (GPx) Assay. GPx activity was
determined according to the method described by Hussain et
al. [23]. Glutathione peroxidase (GPx) is a radical-scavenging
enzyme that catalyzes the reduction of hydrogen peroxide
(H
2
O
2
) and lipid peroxide (ROOH) using glutathione (GSH),
resulting in the formation of oxidized glutathione (GSSH)
and H
2
O. Glutathione reductase (GR) subsequently catalyzes
GSSH by reacting with nicotinamide adenine dinucleotide
phosphate (NADPH) yielding GSH and NADP+. The gen-
eration of NADP+ was measured spectrophotometrically at
340 nm relative to a blank sample and a standard curve was
generated from GPx solutions. GPx activity was expressed as
units/mg protein, where protein concentrationwasmeasured
using the method of Lowry et al. [24].
2.7. Superoxide (𝑂2−∙) Anion Assay. The O2−∙ levels in the
samples were determined by spectrophotometric measure-
ment based on the xanthine/xanthine oxidase (XO) sys-
tem involving the conversion of yellow nitro blue tetra-
zolium (NBT) to blue formazan. Reactions contained EDTA,
NBT, xanthine, XO, and samples were assessed at 560 nm
relative to a standard curve generated using 4-hydroxy-
2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL). Data were
expressed as % inhibition of O
2
−∙ [25].
2.8. Biochemical Assays in Plasma. Blood for biochemical
analysis was collected of 100𝜇L from the animals prior
to treatment via the lateral tail vein and 500 𝜇L after
APAP-induced hepatotoxicity induction through heart. The
blood was centrifuged (1600 g, 15min, 4∘C) to isolate the
serum, which was subsequently analyzed with a FUJI DRI-
CHEM 7000V (Fujifilm, Japan) for biochemical liver activ-
ities of albumin (ALB), alkaline phosphatase (ALP), aspar-
tate aminotransferase (AST), and alanine aminotransferase
(ALT).
2.9. Liver Histopathology. The liver tissues fixed in 10%
neutral buffered formalin solution were cleaned in running
water before being processed for further histopathological
examination. Paraffin-embedded tissues were sectioned (5
𝜇m thickness), stained with hematoxylin and eosin (H&E),
assessed for histopathological changes by light microscopy,
and graded blindly and independently using the modified
method described by Wood et al. [26]. Grades (0–5) were as
follows: 0, no lesions; 1, minimal lesions, only necrotic cells
at the first cell level from the central vein; 2, mild lesions,
necrotic cells extending two to three cell levels from the
central vein; 3, moderate lesions, necrotic cells extending
three to six cell levels within peripheral distribution; 4,
marked lesions, the same as in 3 but with necrosis extruding
to another central vein; and 5, lesions more severe than those
in 4, with progressive centrilobular necrosis throughout the
section.
2.10. Statistical Analysis. Data are expressed as mean ± SEM.
Groups were compared by one-way analysis of variance
(ANOVA) followed by a post hoc multiple comparison test
(Tukey’s method) using SPSS version 16.0. Differences with
𝑝 < 0.05 were considered statistically significant.
3. Results
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Figure 3: Size distribution of RNPN (a) and nRNP (b) assessed by dynamic light scattering (DLS).
3.1. The Size and Distribution of RNPN and nRNP. The
DLS measurements confirmed the unimodal distribution of
nanoparticles in the nanometer size range with no particle
aggregation (Figure 3).Theparticle size and distributionwere
found to be 22.140±0.307 nmand 0.139±0.008 for RNPN and
58.853 ± 0.696 nm and 0.205 ± 0.004 for nRNP, respectively.
From the EPR spectrum of RNPN, the amount of nitroxide
radical in RNPN (12.5mg/mL) was 15.4mM.
3.2. Effects ofRNPN on SerumALB, ALP, ALT, andAST Levels.
Hepatotoxicity was determined by quantitative analysis of
ALB, ALT, AST, and ALP levels as shown in Figure 4. Serum
ALB, ALT, AST, and ALP levels in control mice were 1.9875±
0.2997 g/dL, 23.75±4.301U/L, 91.25±7.995U/L, and 177.5±
10.915U/L, respectively. The NSS + APAP-treated group
exhibited decreased ALB levels, while the ALT, AST, and
ALP levels in the serum of the animals in this group were
significantly elevated compared to those measured for the
control group (𝑝 < 0.001). Interestingly, the ALT, AST, and
ALP levels in the RNPN + APAP-treated animals did not
differ from those in the NAC + APAP-treated group but
differed significantly from those in the NSS + APAP-treated
group (𝑝 < 0.001), indicating that RNPN suppressed the
adverse effects of APAP in mice. Despite the same dose of
nitroxide radicals being administered in both groups, the
protective effect of RNPN was stronger than that of the low
molecular weight (LMW) TEMPO, especially in terms of
ALT, AST, and ALP levels.
3.3. Effects of Treatments on Prothrombin Time. All blood
samples were tested for prothrombin time (Figure 5). The
NAC + APAP-treated animals exhibited a significantly pro-
longed prothrombin time (24.778 ± 3.308 s) compared with
the prothrombin times measured in the control (13.444 ±
0.882 s) and NSS + APAP (13.375 ± 1.84 s) group animals
(𝑝 < 0.001). Prothrombin time, one of the major side
effects of NAC, results in hepatocellular necrosis or dissem-
inated intravascular coagulation (DIC). Interestingly, RNPN
+ APAP treatment did not prolong prothrombin time despite
exhibiting strong therapeutic effects as stated above.
3.4. Effects on MDA Levels, GPx Activity, and % Inhibition
of 𝑂2−∙. The levels of MDA, the GPx activity, and the %
inhibition of O
2
−∙ measured in the livers of all groups are
presented in Figure 6. Liver MDA levels were found to be
elevated in theNSS +APAP group compared with the control
group, whileGPx activity and% inhibition ofO
2
−∙ were lower
in the NSS + APAP group compared with the control group
(13.251±0.365 nmol/mg tissue versus 5.784±1.015 nmol/mg
tissue, 1.660 ± 0.207 units/mg protein versus 3.489 ± 0.168
units/mg protein, and 21.604±1.969%versus 47.237±3.505%,
resp.; 𝑝 < 0.001). Remarkably, RNPN + APAP induced a
noticeable decrease in MDA levels relative to control levels,
whereas GPx activity and % inhibition of O
2
−∙ were found to
be elevated in the RNPN + APAP group compared with the
control group (7.558 ± 1.101 nmol/mg tissue versus 13.251 ±
0.365 nmol/mg tissue, 3.178 ± 0.201 units/mg protein versus
1.660 ± 0.207 units/mg protein, and 44.881 ± 1.749% versus
21.604 ± 1.969%, resp.; 𝑝 < 0.01). No significant differences
in the MDA levels, the GPx activity, and the % inhibition of
O
2
−∙ were observed between the RNPN + APAP- and NAC +
APAP-treated groups. These findings again demonstrate the
protective effect of RNPN to be significantly stronger than
that of LMW TEMPO.
3.5. Histopathological Examinations of APAP-Induced Liver
Toxicity. After seven days of treatment, liver tissues were
taken from the animals of all groups and were subjected
Oxidative Medicine and Cellular Longevity 5
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Figure 4: Biochemical liver function in terms of (a) ALB, (b) ALT, (c) AST, and (d) ALP activities after treatment for 7 days and APAP-
induced hepatotoxicity. Data were expressed as mean ± SEM, ∗versus control group, 𝑝 < 0.001; ∗∗versus control group, 𝑝 < 0.01; #versus
NSS + APAP-treated group, 𝑝 < 0.001; oversus RNPN + APAP-treated group, 𝑝 < 0.05; 𝑛 = 8mice/group.
to histological analysis (Figure 7). The livers from the ani-
mals in the control, NAC + APAP, and RNPN + APAP
groups had an overall smooth appearance and normal
color. The control group livers were further found to have
normal lobular morphology and hepatocytes with well-
defined sinusoids (Figure 7(a)). The hepatic injury in the
mice treated with APAP (2.5mg/kg BW dissolved in normal
saline) manifested as inflammatory infiltration, swelling,
hemorrhage, and necrosis involving mainly the centrilobular
zone (Figure 7(b)). Mild congestion of sinusoidal spaces was
observed in the centrilobular area of the livers of NAC
+ APAP-treated mice (Figure 7(c)). The livers of the mice
6 Oxidative Medicine and Cellular Longevity
0
5
10
15
20
25
30
Ti
m
e (
s)
Prothrombin time
RN
PN
+ 
A
PA
P
C
on
tro
l
N
SS
 +
 A
PA
P
N
AC
 +
 A
PA
P
TE
M
PO
 +
 A
PA
P
nR
N
P 
+ 
A
PA
P
∗, #
Figure 5: Effects of treatments on prothrombin time after treatment
for 7 days. Data represent mean ± SEM, ∗versus control group,
𝑝 < 0.001; #versus NSS + APAP-treated group, 𝑝 < 0.001; 𝑛 = 8
mice/group.
treated with LMW TEMPO and nRNP appeared hyper-
emic, mottled and were fragile (Figures 7(d) and 7(e)).
Remarkably, the livers of the mice treated with RNPN did
not reveal any significant microscopic changes relative to
control tissue (Figure 7(f)). These findings are in agreement
with the histopathological scale analysis of the liver sections
(Figure 8): the RNPN-treated group exhibited significantly
less severe hepatic injury than the NSS, TEMPO, and blank
micelle-treated groups (𝑝 < 0.001).
4. Discussion
The nanoparticle is one of the novel drug carriers for thera-
peutic and diagnostic objectives which has several potential
effects in improving accumulation and bioavailability of drug
in target side thereby suppressed immunogenicity or drug
resistance and finally reducing adverse effects. Additionally,
nanoparticles also promote drug solubility, controlled and
sustained drug release, decreased drug elimination, and
delivered more drugs combination treatment for synergistic
effect [27–29].
Liver injury induced by APAP is one of the most causes
of ALF worldwide and the mortality rate of ALF is ∼20–
40% [3, 4]. Characteristics of APAP-induced ALF include
high levels of liver ALT, AST, and ALP enzymes after 24–72 h
[30, 31]. Here, we show that NSS + APAP treatment raises
the levels of ALT, AST, and ALP, while lowering the level of
ALB, indicating successful preparation of the APAP-induced
hepatotoxicity model. Treatment with NAC or RNPN, on
the other hand, was shown to suppress these APAP-induced
increases. Treatment with LMW TEMPO and nRNP did not
have the same suppressive effect. In addition, our previous
research finding found that RNPN at dose of 300mg/kg BW
via oral administration for 1 month in mice did not show any
toxicity in several organs including liver [20].
At therapeutic doses, about 90% of APAP is elimi-
nated via sulfation or glucuronidation pathways [32, 33]
and another 5% is metabolized by cytochrome P450 2E1
(CYP2E1) toNAPQI [34, 35].TheNAPQI subsequently binds
to glutathione (GSH) to produce mercuric acid and cysteine
conjugates before being eliminated from the body [11]. An
overdose of APAP may result in the depletion of GSH and
cause NAPQI-induced hepatic cell injury [11, 36–39]. Our
GPx activity results showed that RNPN treatment increased
GPx activity compared to treatment with NSS, TEMPO, or
nRNP, indicating the elevation of GSH level like NAC-treated
group.
The production of ROS including hydrogen peroxide,
hydroxyl radicals, and superoxide anions can be enhanced
by NAPQI. Lipid peroxidation, DNA, and protein oxidation,
as well as a decrease in radical-scavenging enzymes of GPx
and superoxide dismutase (SOD) have also been reported
in APAP-induced liver injury [40–42]. This mechanism has
been proposed as a key player in the oxidative stress and
hepatic injury in APAP-induced hepatotoxicity [39–43] and
we thereforemeasured lipid peroxidation, and% inhibition of
O
2
−∙ in this study to confirm ROS production in our APAP-
induced hepatotoxicity model. Interestingly, treatment with
RNPN was found to diminish lipid peroxidation compared to
treatment with NSS, TEMPO, or nRNP, while % inhibition
of O
2
−∙ was also higher in the RNPN-treated group com-
pared with the NSS-, NAC-, TEMPO-, and nRNP-treated
groups. Although LMW TEMPO, like RNPN, possesses ROS
scavenging activity, the scavenging efficiency of the LMW
TEMPO is lower than that of the RNPN, probably due to the
rapid elimination, easy metabolism, and marked disturbance
of normal redox reaction in normal cells. We have previ-
ously reported that only 5–7% of PEG-b-PMNT internalizes
in blood stream by oral administration [20]. Prolonged
circulation tendency of the internalized PEG-b-PMNT in
blood stream might improve an access to liver tissue, which
might improve therapeutic efficiency as comparedwith LMW
TEMPO.
The standard treatment for APAP-induced liver toxicity
is NAC, which acts as a GSH precursor to increase the
GSH reservoir. Treatment with NAC, however, triggers an
impaired coagulation cascade, which is the reason why
prothrombin time was assessed in this study. Mice in the
NAC + APAP-treated group were shown to have significantly
prolonged prothrombin times compared to other groups (𝑝 <
0.001), while themice in the RNPN +APAP-treated group did
not exhibit this side effect.
The findings from the hepatic function analyses in
this study were confirmed by the histopathological changes
observed by microscopic analysis. In the NSS + APAP,
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Figure 6: Effects of treatment for 7 days on (a)% inhibition ofO
2
−∙, (b) GPx activity, and (c)MDA levels. Data representmean± SEM, ∗versus
control group, 𝑝 < 0.001; ∗∗versus control group, 𝑝 < 0.01; #versus NSS + APAP-treated group, 𝑝 < 0.01; oversus RNPN + APAP-treated
group, 𝑝 < 0.05; 𝑛 = 8mice/group.
TEMPO + APAP, and nRNP + APAP groups, inflamma-
tory infiltration of lymphocytes, vacuolation, swelling, and
centrilobular necrosis were observed, while pretreatment
with RNPN and NAC was found to prevent these histo-
logical changes. Mice in the NAC + APAP-treated group,
however, exhibited mild changes in hepatocyte and sinusoid
arrangement. Furthermore, the previous study showed that
the RNPN treatment ameliorates nonalcoholic steatohepatitis
NASH fibrosis via the decrease of hepatic stellate cell activa-
tion marker of alpha-smooth muscle actin (𝛼-SMA) [44].
We report here that RNPN successfully ameliorated
APAP-induced hepatotoxicity in mice as demonstrated by
decreased levels of the hepatic injury markers ALT, AST,
and ALP and increased ALB levels. The observed protective
effects of RNPN may be due to antioxidant effects as shown
by the reduced lipid peroxidation, increased GPx activity,
and increased % inhibition of O
2
−∙. The histopathological
analysis conducted in this study did not reveal any toxicity
by RNPN. Therefore, the patients who are long-term users
of APAP need to suppress liver damage. So, combination of
APAP with RNPN is also very interesting strategy to suppress
hepatotoxicity.
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Figure 7: Hepatoprotective effect of treatments in mice with APAP-induced liver damage. (a) control group. (b) APAP-induced group. ((c)–
(f)) APAP group treatedwith (c) 600mg/kgBWofNAC, (d) 15.4mMof LMWTEMPO, (e) 12.5mg/mLof nRNP, (f) and 12.5mg/mLof RNPN.
Liver sections were stained with hematoxylin and eosin (×400). CV: central vein; S: sinusoids; KC; Kupffer cell; N: necrosis; I: inflammation;
H: hemorrhage.
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Figure 8: Histopathological changes in liver tissue due to APAP-
induced hepatotoxicity. Data representmean± SEM, ∗versus control
group, 𝑝 < 0.001; ∗∗versus control group, 𝑝 < 0.05; #versus NSS
+ APAP-treated group, 𝑝 < 0.001; oversus RNPN + APAP-treated
group, 𝑝 < 0.001; 𝑛 = 5 samples/group.
5. Conclusion
The findings of this study indicate that RNPN has a hep-
atoprotective effect against APAP-induced liver injury via
antioxidant properties decreasing lipid peroxidation while
increasing GPx activity and the % inhibition of O
2
−∙. Treat-
ment with RNPN furthermore shows no side effect of coag-
ulation cascade impairment, indicating that RNPN may be
a more effective treatment for APAP-induced hepatotoxicity
thanNAC.Our findings lead us to conclude that antioxidative
nanomedicine is a promising strategy for improving thera-
peutic effects by suppressing disturbances of normal redox
reactions in healthy cells.
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